Press Release
Share
Physical Sciences Inc. (PSI), has been awarded a research program from the National Institutes of Health (NIH) to develop a novel technique to identify amyloid β-protein (Aβ) deposits in the retina as a biomarker for Alzheimer’s disease (AD).
PSI will develop an optical imaging technique capable of non-invasively identifying specific chemical compounds in vivo in the retina with cellular-level resolution and without the use of contrast agents. PSI will validate the ability of this technique to identify early indications of AD.
Although AD cannot yet be treated with the intent to cure, sufficient early diagnosis will facilitate intervention with available therapeutics, adding years of productive quality time to the patient’s life. However, the lack of suitable diagnostic tools for both in vivo rapid screening of Aβ aggregation and early detection of AD pathology poses severe limitations. Current available structural, functional, and metabolic brain imaging methods are not yet suitable for repeated population screening in the preclinical stages. They are either limited by the use of unsafe ionizing isotopes (radioactivity), involve high costs, have low availability, or provide reduced resolution or specificity. An alternative non-invasive approach to visualize Aβ plaques in AD patients may be achieved through high-resolution optical imaging of the retina, knowing that Aβ plaques form in retinal layers and share properties with those in the brain.
The retina, as an extension of the brain, is the only part of the central nervous system that can be imaged non-invasively at sub-cellular resolutions. Human postmortem histopathological studies have shown accumulation of Aβ in the retinas of those with confirmed AD, principally in the inner-retinal layers. PSI is developing a multispectral adaptive optics-based non-invasive optical imaging technique that will enable in vivo cellular-level resolution for early detection of Aβ presence in the retina and will facilitate a path to understanding the onset of various neurodegenerative diseases. This effort will build on our expertise in high-resolution retinal imaging and spectral analysis.
For more information, contact:
Dr. Nicusor Iftimia
Area Manager, Biomedical Optics Technology
iftimia@psicorp.com
Physical Sciences Inc.
Telephone: (978) 689-0003